Illumina Inc
$ 120.93
-2.22%
10 Apr - close price
- Market Cap 18,490,198,000 USD
- Current Price $ 120.93
- High / Low $ 125.93 / 118.30
- Stock P/E 22.19
- Book Value 17.80
- EPS 5.45
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.33 %
- 52 Week High 155.53
- 52 Week Low 69.83
About
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
Analyst Target Price
$136.11
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-11-03 | 2025-07-31 | 2025-05-08 | 2025-02-06 | 2024-11-04 | 2024-08-06 | 2024-05-02 | 2024-02-08 | 2023-11-09 | 2023-08-09 | 2023-04-25 |
| Reported EPS | 1.35 | 1.34 | 1.19 | 0.97 | 0.86 | 1.14 | 0.36 | 0.09 | 0.14 | 0.33 | 0.32 | 0.08 |
| Estimated EPS | 1.22 | 1.17 | 1.01 | 0.94 | 0.92 | 0.88 | 0.9 | 0.04 | 0.02 | 0.12 | 0.02 | 0.03 |
| Surprise | 0.13 | 0.17 | 0.18 | 0.03 | -0.06 | 0.26 | -0.54 | 0.05 | 0.12 | 0.21 | 0.3 | 0.05 |
| Surprise Percentage | 10.6557% | 14.5299% | 17.8218% | 3.1915% | -6.5217% | 29.5455% | -60% | 125% | 600% | 175% | 1500% | 166.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ILMN
2026-04-02 11:10:44
Coherent Market Insights has published a new research study on the Global "AAV Genome Sequencing Service Market" forecasting growth through 2033. The report segments the market by type, application, end-user, and region, identifying key players like Thermo Fisher Scientific, Illumina, and Danaher Corporation. It aims to provide a comprehensive analysis of market trends, drivers, restraints, competitive landscape, and regional dynamics to aid strategic decision-making.
2026-04-01 17:24:00
Illumina Inc. (ILMN) saw its stock rally by 2.73% to $126.63 on Wednesday, outperforming the broader market. This marked the third consecutive day of gains for Illumina, as the S&P 500 Index and Dow Jones Industrial Average also rose. The article highlights Illumina's strong performance relative to its competitors on a positive trading day.
2026-03-31 00:09:11
This article provides the current stock price quote and chart for Illumina Inc (ILMN). It indicates that the content is related to online trading via the Capital.com smart investment app.
2026-03-27 17:25:00
Illumina Inc. (ILMN) stock underperformed on Friday, falling 5.41% to $117.67. This occurred during a broad market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing significant losses. This marks the second consecutive day of losses for Illumina's stock.
2026-03-25 21:40:44
Illumina has recently expanded its collaborations with Labcorp and entered a new consortium, driving its stock momentum, with a 5.2% 30-day return. Despite recent gains, the 1-year return is strong, contrasting with weaker 3 and 5-year returns, indicating a recent upturn. The company is currently valued at a discount to analyst targets and an intrinsic value estimate of $136.05, raising questions about whether current pricing fully accounts for future growth from these new alliances.
2026-03-24 21:39:23
Illumina Inc. is facing significant challenges, including regulatory scrutiny over its past Grail acquisition and a slowdown in the biotech sector. Despite a robust balance sheet and ongoing R&D investments, the company's stock is under pressure from softening demand in genomic sequencing, increased competition, and lingering legal ramifications from the Grail divestiture. Investors are closely watching if Illumina can successfully navigate these headwinds and recover its growth trajectory.
